Adverum Files Investor Presentation Highlighting Significant Strategic Progress and Purpose-Built Board to Oversee Stockholder Value CreationGlobeNewsWire • 04/22/21
Adverum Mails Letter to Stockholders Highlighting World-Class Board of Directors Overseeing Successful ADVM-022 Commercial LaunchGlobeNewsWire • 04/21/21
The Sonic Fund II, L.P. Files Definitive Proxy Statement and Sends Letter to Stockholders of Adverum Biotechnologies, Inc.Business Wire • 04/19/21
Adverum Biotechnologies to Present New Data from the OPTIC Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at ARVO 2021GlobeNewsWire • 04/16/21
Adverum Announces Senior Appointments for Patient Access and Clinical Operations as ADVM-022 Advances Toward Global Phase 3 TrialsGlobeNewsWire • 03/30/21
Adverum Announces Board Slate for 2021 Annual Meeting and Reiterates Commitment to Stockholder Value CreationGlobeNewsWire • 03/17/21
Is the Options Market Predicting a Spike in Adverum Biotechnologies (ADVM) Stock?Zacks Investment Research • 03/05/21
Adverum Biotechnologies, Inc's (ADVM) CEO Laurent Fischer on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 03/02/21
Adverum Biotechnologies (ADVM) Reports Q4 Loss, Misses Revenue EstimatesZacks Investment Research • 03/01/21
Adverum Announces Shortened Timelines and Clear Development Path for ADVM-022 Intravitreal Gene Therapy in Wet AMD, Reports Recent Business Progress and Fourth Quarter 2020 Financial ResultsGlobeNewsWire • 03/01/21
Adverum to Host Conference Call and Webcast to Highlight Updated ADVM-022 Development Plans in Wet AMD, Recent Business Progress, and Fourth Quarter 2020 Financial ResultsGlobeNewsWire • 02/22/21
Adverum to Present Data from the OPTIC Phase 1 Trial with ADVM-022 Intravitreal Gene Therapy in Wet AMD at the Angiogenesis, Exudation, and Degeneration 2021 Virtual MeetingGlobeNewsWire • 02/10/21
All You Need to Know About Adverum Biotechnologies (ADVM) Rating Upgrade to BuyZacks Investment Research • 01/11/21
Implied Volatility Surging for Adverum Biotechnologies (ADVM) Stock OptionsZacks Investment Research • 01/08/21
Adverum Biotechnologies Announces New GMP Gene Therapy Manufacturing FacilityGlobeNewsWire • 01/07/21
Adverum Biotechnologies Presents at the Piper Sandler Annual Virtual Healthcare ConferenceGlobeNewsWire • 11/23/20
Adverum Biotechnologies Announces Positive Interim Data from Cohorts 1-4 from OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMDGlobeNewsWire • 11/14/20
Adverum Biotechnologies (ADVM) Reports Q3 Loss, Misses Revenue EstimatesZacks Investment Research • 11/05/20
Adverum Biotechnologies to Present New Data from the OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at AAO 2020 VirtualGlobeNewsWire • 10/20/20
Adverum Biotechnologies to Participate in the Cantor Virtual Global Healthcare ConferenceGlobeNewsWire • 09/10/20
Adverum Biotechnologies Announces Closing of $217 Million Public Offering of Common StockGlobeNewsWire • 08/18/20